We are live on
!
Find out more
PC
Polar Capital Portfolio holdings
AUM
$13.5B
1-Year Est. Return
55.9%
This Fund
S&P 500
This Quarter
Est. Return
+34.87%
1 Year Est. Return
+55.9%
3 Year Est. Return
+127.44%
5 Year Est. Return
+269.08%
10 Year Est. Return
–
AUM
$11.6B
AUM Growth
+$2.27B
(+24%)
Cap. Flow
-$278M
Cap. Flow
% of AUM
-2.4%
Top 10 Holdings %
Top 10 Hldgs %
30.23%
Holding
354
New
65
Increased
75
Reduced
125
Closed
74
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
UnitedHealth
UNH
|
+$106M |
| 2 |
Meta Platforms (Facebook)
META
|
+$106M |
| 3 |
PayPal
PYPL
|
+$105M |
| 4 |
XLNX
Xilinx Inc
XLNX
|
+$99.5M |
| 5 |
Ciena
CIEN
|
+$86.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AbbVie
ABBV
|
+$85.6M |
| 2 |
Bristol-Myers Squibb
BMY
|
+$84.6M |
| 3 |
Amazon
AMZN
|
+$72.7M |
| 4 |
Intel
INTC
|
+$72.2M |
| 5 |
RingCentral
RNG
|
+$71.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 36.14% |
| 2 | Healthcare | 19.11% |
| 3 | Financials | 17.15% |
| 4 | Communication Services | 12.94% |
| 5 | Consumer Discretionary | 7.63% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
101
Analog Devices
ADI
$172B
| $29.9M | 0.26% |
243,582
-162,605
| -40% | -$17.9M |
|
|
ALXN
102
DELISTED
Alexion Pharmaceuticals
ALXN
| $29.7M | 0.26% |
265,000
-80,934
| -23% | -$8.59M |
|
103
Envista
NVST
$4.62B
| $29.5M | 0.25% |
1,397,625
-352,555
| -20% | -$6.61M |
|
104
Ametek
AME
$53.9B
| $28.3M | 0.24% |
316,656
-109,872
| -26% | -$9.22M |
|
105
Elevance Health
ELV
$81.5B
| $27.9M | 0.24% |
106,110
-100,353
| -49% | -$26.8M |
|
106
Teleflex
TFX
$5.96B
| $27.7M | 0.24% |
+76,130
| New | +$26.3M |
|
107
Agilent Technologies
A
$39.6B
| $27.7M | 0.24% |
313,414
-283,044
| -47% | -$23.2M |
|
108
Addus HomeCare
ADUS
$2.22B
| $27.2M | 0.23% |
293,488
+60,485
| +26% | +$5.23M |
|
109
Pinterest
PINS
$13.7B
| $26.9M | 0.23% |
1,211,618
-2,576,163
| -68% | -$50.3M |
|
110
Icon
ICLR
$13.7B
| $25.8M | 0.22% |
152,871
-84,354
| -36% | -$13.3M |
|
111
James River Group Holdings
JRVR
$219M
| $24.8M | 0.21% |
550,000
| – | – |
|
112
Tactile Systems Technology
TCMD
$618M
| $24.7M | 0.21% |
595,642
+392,043
| +193% | +$18.4M |
|
113
US Foods
USFD
$22.5B
| $24.3M | 0.21% |
1,232,028
-206,692
| -14% | -$3.95M |
|
|
AVDL
114
DELISTED
Avadel Pharmaceuticals
AVDL
| $24.1M | 0.21% |
+2,978,915
| New | +$26.3M |
|
115
First American
FAF
$7.98B
| $22.8M | 0.2% |
475,000
+40,000
| +9% | +$1.89M |
|
116
Dolby
DLB
$4.97B
| $22.6M | 0.2% |
343,265
-208,468
| -38% | -$12.5M |
|
117
SS&C Technologies
SSNC
$18.9B
| $22.6M | 0.19% |
399,468
-169,374
| -30% | -$9.23M |
|
118
Johnson & Johnson
JNJ
$640B
| $22.4M | 0.19% |
159,352
-92,951
| -37% | -$13.5M |
|
119
Altria Group
MO
$125B
| $22.4M | 0.19% |
570,813
-149,580
| -21% | -$5.84M |
|
120
Enovis
ENOV
$1.74B
| $22.3M | 0.19% |
463,948
-81,659
| -15% | -$3.61M |
|
121
RLI Corp
RLI
$6.02B
| $22M | 0.19% |
535,000
-48,000
| -8% | -$1.89M |
|
|
YMAB
122
DELISTED
Y-mAbs Therapeutics
YMAB
| $21.9M | 0.19% |
506,083
+125,000
| +33% | +$4.73M |
|
123
Intercontinental Exchange
ICE
$87.2B
| $21.4M | 0.18% |
233,824
-35,998
| -13% | -$3.3M |
|
124
Citigroup
C
$213B
| $21M | 0.18% |
411,094
-50,924
| -11% | -$2.42M |
|
125
Merck
MRK
$322B
| $20.9M | 0.18% |
282,722
-440,891
| -61% | -$33.2M |
|
Similar funds
ECM
FAAS
WAM
FS
NIMC
TI
VIM
PS
Polar Capital's Q2 2020 Portfolio in Review
As of Q2 2020, Polar Capital held 354 positions worth $11.6B, up 24% from $9.31B the previous quarter. Its ten largest holdings account for 30% of the portfolio.
Polar Capital's Q2 2020 filing shows 65 new, 75 increased, 125 reduced and 74 closed positions. Its largest new stake was TripAdvisor: 3,886,053 shares worth $73.9M. The largest sale was AbbVie, an estimated $85.6M.
By sector, the portfolio is most concentrated in Technology at 36% of assets, up from 36% a quarter earlier, followed by Healthcare and Financials.
- Polar Capital's largest Q2 2020 buy was TripAdvisor: 3,886,053 shares worth $73.9M.
- Polar Capital added most to UnitedHealth in Q2 2020, an estimated $106M increase.
- Polar Capital's biggest Q2 2020 reduction was Bristol-Myers Squibb, cutting an estimated $84.6M.
- Polar Capital fully exited AbbVie in Q2 2020, selling an estimated $85.6M.
- Polar Capital's ten largest holdings make up 30% of its $11.6B portfolio in Q2 2020.
- Polar Capital opened 65 new positions and closed 74 in Q2 2020.
- Polar Capital's portfolio value rose 24% quarter-over-quarter to $11.6B.
Based on Polar Capital's 13F filing for Q2 2020, filed 14 Aug 2020.